Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy

Journal of Clinical Pharmacology

Volumn 36, Issue 1, 1996, Pages 35-41

  Tisdale, James E ^a,b   Rudis, Maria I ^b   Padhi, I Desmond ^a,b   Borzak, Steven ^b   Svensson, Craig K ^a   Webb, Charles R ^b   Acciaioli, Joseph ^b   Ware, Joseph A ^a,b   Krepostman, Abraham ^b   Zarowitz, Barbara J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROCAINAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; MALE;

EID: 9044242092     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04149.x     Document Type: Article

References (27)

1. Paranicas JD, Greenspan AM: Procainamide. In, Horowitz LN (ed.): Current Management of Cardiac Arrhythmias. Philadelphia: BC Decker. 1991:351-357.
2. Hondeghem LM, Mason JW: Agents used in cardiac arrhythmias. In, Katzung BG (ed.): Basic and Clinical Pharmacology. Fourth edition. Norwalk. CT: Appleton & Lange, 1989;165-182.
3. Coyle JD, Lima JJ: Procainamide. In, Evans WE, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Third edition. Spokane, WA: Applied Therapeutics, 1992;22-1-22-33.
4. Noguchi JK, Gill MA: Cardiac arrhythmias. In, Herfindal ET, Gourley DR, Hart LL (eds.): Clinical Pharmacy and Therapeutics. Fifth edition. Baltimore: Williams & Wilkins, 1992;635-676.
5. American Society of Hospital Pharmacists: AHFS Drug Information. Bethesda: American Society of Hospital Pharmacists, 1994.
6. Koch-Weser J, Klein SW: Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA 1971;215:1454-1460.
7. du Souich P, Erill S: Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure. Eur J Clin Pharmacol 1978;14:21-27.
8. Lima JJ, Goldfarb AL, Conti DR, Golden LH, Bascomb BL, Benedetti GM, Jusko WJ: Safety and efficacy of procainamide infusions. Am J Cardiol 1979;43:98-105.
9. Grasela TH, Sheiner LB: Population pharmacokinetics of procainamide from routine clinical data. Clin Pharmacokinet 1984;9: 545-554.
10. Bauer LA, Black D, Gensler A, Sprinkle J: Influence of age, renal function and heart failure on procainamide clearance and n-acetyl-procainamide serum concentrations. Int J Clin Pharmacol Ther Toxicol 1989;27:213-216.
11. Baker DW, Konstam MA, Bottorff M, Pitt B: Management of heart failure. I. Pharmacologic treatment. JAMA 1994;272:1361-1366.
12. Creager MA, Halperin JL, Bernard DB, Faxon DP, Melidossian CD, Gavras H, Ryan TJ: Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation 1981;64:483-489.
13. Cleland JG, Dargie HJ, Ball SG, Gillen G, Hodsman GP, Morton JI, East BW, Robertson I, Ford I, Robertson JI: Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985;54:305-312.
14. Kosoglou T, Vlasses PH: Drug interactions involving renal transport mechanisms: an overview. DICP Ann Pharmacother 1989;23:116-122.
15. Grant DM, Tang BK, Campbell ME, Kalow W: Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 1986;21: 454-458.
16. Olsen H, Morland J: Ethanol-induced increase in procainamide acetylation in man. Br J Clin Pharmacol 1982;13:203-208.
17. Tisdale JE, Rudis MI, Padhi ID, Svensson CK, Webb CR, Borzak S, et al: Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in human subjects. J Clin Pharmacol 1995;35:902-910.
18. Tang BK, Kadar D, Kalow W: An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 1987;42:509-313.
19. Tang BK, Zubovits T, Kalow W: Determination of acetylated caffeine metabolites by high-performance exclusion chromatography. J Chromatogr 1986;375:170-173.
20. MacKichan JJ, Coyle JD, Shields BJ, Boudoulas H, Lima JJ: Fluoroimmunoassays for procainamide and N-acetylprocainamide compared with a liquid-chromatographic method. Clin Chem 1984;30:768-73.
21. Liu L-L, Knowlton PW, Svensson CK: Effect of amiodarone on the disposition of procainamide in the rat. J Pharm Sci 1988;77: 662-665.
22. Rocci ML, Jusko WJ: LAGRAN program for area and moments in pharmacokinetic analysis. Comput Prog Biomed 1983;16:203-216.
23. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications. Second edition. Philadelphia: Lea & Febiger, 1989.
24. Cody RJ, Ljungman S, Covit AB, Kubo SH, Sealey JE, Pondolfino K, et al: Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int 1988;34:361-367.
25. Hepner GW, Vesell ES, Tantum KR: Reduced drug elimination in congestive heart failure: studies using aminopyrine as a model drug. Am J Med 1978;65:271-276.
26. Kessler KM, Kayden DS, Estes DM, Koslovskis PL, Sequeira R, Trohman RG, et al: Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. J Am Coll Cardiol 1986;7:1131-1139.
27. Francis GS: Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence, and prognosis. Am J Cardiol 1986;57:3B-7B.